Skip to main content

Part of the book series: Contemporary Endocrinologyâ„¢ ((COE))

  • 1738 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 249.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 2006;43(4):661–672.

    Article  PubMed  CAS  Google Scholar 

  2. Roti E, Minelli R, Giuberti T, et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med 1996;101:482–487.

    Article  PubMed  CAS  Google Scholar 

  3. Preziati D, La Rosa L, Covini G, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 1995;132:587–593.

    PubMed  CAS  Google Scholar 

  4. Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid 2003;13(6):547–551.

    Google Scholar 

  5. Koh LKH, Greenspan FS, Yeo PPB. Interferon-induced thyroid dysfunction: three clinical presentations and review of the literature. Thyroid 1997;7:891–896.

    PubMed  CAS  Google Scholar 

  6. Crossmit EP, de Metz J, Sauerwein HP, Romijn JA. Biologic responses to IFN-alpha administration in humans. J Interferon Cytokine Res 2000;20:1039–1047.

    Article  Google Scholar 

  7. Sato K, Satoh T, Shizume K, et al. Inhibition of 125I organification and thyroid hormone release by interleukin-1, tumor necrosis factor-alpha, and interferon-gamma in human thyrocytes in suspension culture. J Clin Endocrinol Metab 1990;70(6):1735–1743.

    PubMed  CAS  Google Scholar 

  8. Caraccio N, Giannini R, Cuccato S, et al. Type I interferons modulate the expression of thyroid peroxidase, sodium/iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures. J Clin Endocrinol Metab 2005;90:1156–1162.

    Article  PubMed  CAS  Google Scholar 

  9. Monzani F, Caraccio N, Dardano A, Ferrannini E. Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin Exp Med 2004;3:199–210.

    Article  PubMed  CAS  Google Scholar 

  10. Oppenheim Y, Ban Y, Tomer Y. Interferon induced autoimmune thyroid disease (AITD): a model for human autoimmunity. Autoimmun Rev 2004;3(5):388–393.

    Article  PubMed  CAS  Google Scholar 

  11. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87(2):489–499.

    Article  PubMed  CAS  Google Scholar 

  12. Carella C, Amato G, Biondi B, et al. Longitudinal study of antibodies against thyroid in patients undergoing interferon-alpha therapy for HCV chronic hepatitis. Horm Res 1995;44(3):110–114.

    Article  PubMed  CAS  Google Scholar 

  13. Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol 1994;89(3):399–403.

    PubMed  CAS  Google Scholar 

  14. Imagawa A, Itoh N, Hanafusa T, et al. Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis. J Clin Endocrinol Metab 1995;80:922–926.

    Article  PubMed  CAS  Google Scholar 

  15. Carella C, Mazziotti G, Amato G, Braverman LE, Roti E. Clinical review 169: Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab 2004;89(8):3656–3661.

    Article  PubMed  CAS  Google Scholar 

  16. Mazziotti G, Sorvillo F, Stornaiuolo G, et al. Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study. J Endocrinol Invest 2002;25:624–630.

    PubMed  CAS  Google Scholar 

  17. Wong V, Fu AX, George J, Cheung NW. Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol (Oxf) 2002;56(6):793–798.

    Article  CAS  Google Scholar 

  18. Parana R, Cruz M, Lyra L, Cruz T. Subacute thyroiditis during treatment with combination therapy (interferon plus ribavirin) for hepatitis C virus. J Viral Hepat 2000;7(5):393–395.

    Google Scholar 

  19. Minelli R, Valli MA, Di Seclì C, et al. Is steroid therapy needed in the treatment of destructive thyrotoxicosis induced by alpha-interferon in chronic hepatitis C? Horm Res 2005;63(4):194–199.

    Article  PubMed  CAS  Google Scholar 

  20. Carella C, Mazziotti G, Morisco F, et al. Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab 2001;86(5):1925–1929.

    Article  PubMed  CAS  Google Scholar 

  21. Cooper DS. Antithyroid drugs. N Engl J Med 2005;352:905–917.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press,Totowa, NJ

About this chapter

Cite this chapter

Aoun, P., Cooper, D.S. (2008). Interferon-Induced Hyperthyroidism. In: Davies, T.F. (eds) A Case-Based Guide to Clinical Endocrinology. Contemporary Endocrinologyâ„¢. Humana Press. https://doi.org/10.1007/978-1-60327-103-5_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-103-5_5

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-815-7

  • Online ISBN: 978-1-60327-103-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics